Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astera Labs (ALAB) Cash & Equivalents (2023 - 2025)

Astera Labs (ALAB) has disclosed Cash & Equivalents for 3 consecutive years, with $167.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 110.7% year-over-year to $167.6 million, compared with a TTM value of $167.6 million through Dec 2025, up 110.7%, and an annual FY2025 reading of $167.6 million, up 110.7% over the prior year.
  • Cash & Equivalents was $167.6 million for Q4 2025 at Astera Labs, up from $79.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $696.1 million in Q1 2024 and bottomed at $45.1 million in Q4 2023.
  • Average Cash & Equivalents over 3 years is $255.9 million, with a median of $146.9 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents surged 76.4% in 2024, then soared 110.7% in 2025.
  • Year by year, Cash & Equivalents stood at $45.1 million in 2023, then soared by 76.4% to $79.6 million in 2024, then skyrocketed by 110.7% to $167.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for ALAB at $167.6 million in Q4 2025, $79.6 million in Q4 2024, and $126.1 million in Q3 2024.